Clinical Research Directory

Inclusion Criteria: * Capable of giving signed informed consent * Be ≥18 years of age. * Have type 1 or type 2 diabetes mellitus * Have a decrease in vision in the study eye due to diabetic macular edema (DME), with best corrected visual acuity of 78 to 25 letters * Have macular edema on OCT with a CST of ≥ 325 µm * Participants may be either treatment-naïve or previously-treated for DME in their study eye. The number of previously-treated participants is limited. * Additional inclusion criteria apply Exclusion Criteria: * Be pregnant or breastfeeding * History of cataract surgery in the study eye within 90 days of Screening * Has uncontrolled glaucoma in the study eye * Has uncontrolled hypertension * Has had a stroke or myocardial infarction within 180 days * If in the cohort of previously treated for DME participants, prior treatment with intravitreal bevacizumab, aflibercept, faricimab, ranibizumab, conbercept, or other approved anti-VEGF or Anti-VEGF/Anti-Ang-2 therapies within 90 days of randomization. * Additional exclusion criteria apply